The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia Therapeutics and Braveheart Bio the latest to make their intentions known.
Attovia's IPO aims to raise funding for a pipeline of immunology and inflammation (I&I) drug candidates led by ATTO-1310, an IL-31-targeted fusion protein that is being developed for conditions associated with itching (pruritus), including chronic pruritus of unknown origin (CPUO), high-itch atopic dermatitis, cholestatic pruritus, and chronic kidney disease-associated pruritus.
The drug could be a potential rival to other drugs that act on the IL-31 pathway, including Galderma's Nemluvio (nemolizumab), which has been approved as a treatment for atopic dermatitis and rare skin disorder prurigo nodularis and has been tipped as a potential $4 billion-a-year blockbuster. It could also compete with Sanofi and Regeneron's big-selling IL-4 and IL-13-directed Dupixent (dupilumab), which is approved for a broad range of indications, including atopic dermatitis. Both Nemluvio and Dupixent are also being developed for CPUO.
Attovia's pipeline is designed to improve on current therapies for its target diseases, for example, by improving the route of administration, having greater potency, or bioavailability in the body. In the case of ATTO-1310, for example, it hopes to offer less frequent subcutaneous injections than the monthly dosing required with Nemluvio and deliver a stronger blockade of the IL-31 pathway. Phase 2 trials are due to start next year.
Its pipeline also includes ATTO-2306, a bispecific antibody targeting both IL-13 and IL-31, and a triple-acting drug codenamed ATTO-1091 in its pipeline, both of which remain in preclinical development.
San Carlos, California-based Attovia, which was founded in 2023 and has already completed three private funding rounds that raised almost $256 million, plans to list on the Nasdaq under the ATTO symbol.
San Francisco, California-based Braveheart, meanwhile, is developing oral small molecules for cardiovascular diseases, with a pipeline led by BHB-1893, a cardiac myosin inhibitor licensed from Jiangsu Hengrui Pharma last September.
The drug has already been tested in phase 2 for obstructive and non-obstructive forms of hypertrophic cardiomyopathy (HCM) by Hengrui in China, and has advanced into phase 3 testing. Braveheart is hoping to raise funds from its IPO to start international phase 3 trials.
A study in obstructive HCM (LIONHEART-HCM) is due to start before the end of the year, while a second in non-obstructive HCM (NOBLEHEART-HCM) is slated for the first half of next year.
If approved, the drug could be a rival to Bristol Myers Squibb's Camzyos (mavacamten) and Cytokinetics' Myqorzo (aficamten), which are both approved by the FDA for obstructive HCM and in late-stage clinical testing for non-obstructive forms of the disease.
Founded in 2024, Braveheart plans to list on the Nasdaq under the symbol BRVE. It completed a $185 million Series A last November.
https://pharmaphorum.com/news/two-more-biotechs-attovia-and-braveheart-join-ipo-line
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.